个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Long-term safety of icotinib in patients with non-small cell lung cancer: A retrospective, real-world study(Open Access)

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Wen Zhang[1] * ; Yiping Zhang[2] ; Qiong Zhao[3] ; Xiguang Liu[4] ; Likun Chen[5] ; Hongming Pan[6] ; Yuping Li[7] ; You Lu[8] ; Jianjin Huang[9] ; Zhe Zhang[10] ; Kaiqi Du[11] ; Suning Zhang[12] ; Tao Li[13] ; Liqin Lu[14] ; Guangmao Yu[15] ; Yang Wang[16] ; Xiaobin Yuan[16] ; Min Yang[16] ; Yongbin Ma[16] ; Fenlai Tan[16,*1] ;
机构： [1]Department of Cardiothoracic Surgery, the First Affiliated Hospital of People’s Liberation Army General Hospital (304 Hospital), Beijing 100048,China [2]Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China [3]The Affiliated Shulan Hospital, Medical School ofZhejiang Shuren University, Hangzhou 310000, China [4]Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao 266000,China [5]Department of Medical Oncology, Sun-Yet San University Cancer Center, Guangzhou 510060, China [6]Department of Oncology, Sir RunRun Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou 310016, China [7]Department of Respiratory Medicine, the First AffiliatedHospital of Wenzhou Medical University, Wenzhou 325000, China [8]Thoracic Cancer Department, West China Hospital, Sichuan University,Chengdu 610041, China [9]Department of Oncology, the Second Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou 310009,China [10]Department of Thoracic Surgery, Qingdao Municipal Hospital, Qingdao 266011, China [11]Department of Thoracic Surgery, ChinesePeople’s Armed Police Force, Zhejiang Corps Hospital, Hangzhou 314000, China [12]Department of Thoracic Surgery, Shengjing Hospital, ChinaMedical University, Shenyang 110004, China [13]Radiation Therapy Department, Sichuan Cancer Hospital & Institute, Chengdu 610041, China [14]Department of Oncology, Zhejiang Provincial People’s Hospital, Hangzhou 310014, China [15]Department of Cardio-Thoracic Surgery, ShaoxingPeople’s Hospital, Shaoxing 312000, China [16]Betta Pharmaceuticals Co., Ltd, Hangzhou 311100, China
出处：
DOI： 10.21037/jtd.2019.12.115
ISSN：

关键词： Epidermal growth factor receptor (EGFR) Icotinib Long-term safety Non-small cell lung cancer (NSCLC) Tyrosine kinase inhibitor (TKIs)

摘要：
Background: Lung cancer is a global health problem with a high mortality, and the development of target therapy has led to a revolution in the treatment of lung cancer in recent years. Favorable efficacy and safety of icotinib have been demonstrated in patients with non-small cell lung cancer (NSCLC). Currently, minimal data are available to describe the long-term safety of icotinib in NSCLC patients. Methods: We reviewed the safety data from 1,321 advanced NSCLC patients who were treated with icotinib. The primary endpoint was the long-term safety, defined as any adverse drug reactions (ADRs) occurred after 6 months of icotinib administration. Results: Fewer ADRs were noticed over 6 month administration of icotinib than within 6 months in overall population (24.3% vs. 65.4%), and elderly patients (23.6% vs. 66.9%). The majority of ADRs were grade 1–2 in severity over 6 month exposure of icotinib in overall population as well as elderly patients. In overall population, the most common ADRs of icotinib during long-term use were rash (16.4%) and diarrhea (5.3%), while the incidences were 31.8% and 13.2% in the induction period, respectively. In elderly population, the most common ADRs of icotinib during long-term use were rash (15.7%) and diarrhea (4.7%), while the incidences were 27.8% and 14.9% in the induction period, respectively, and more inching was observed in the induction period as compared with long term use (6.3% vs. 0.3%). Conclusions: There was an evidence of decreased frequency of icotinib-induced ADRs over time, and icotinib was well-tolerated in elderly NSCLC patients. © Journal of Thoracic Disease. All rights reserved.

基金：
investigators who participated in the study. Funding: This work was supported by the Betta Pharmaceuticals Co., Ltd (Hangzhou, China), and partly supported by the grant from National Key Special Program for Innovative Drugs (grant number 2012ZX09101103).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类 | 4 区 医学
小类 | 4 区 呼吸系统
最新[2023]版：
大类 | 3 区 医学
小类 | 4 区 呼吸系统
JCR分区：
出版当年[2020]版：
Q3 RESPIRATORY SYSTEM
最新[2023]版：
Q3 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者机构： [1]Department of Cardiothoracic Surgery, the First Affiliated Hospital of People’s Liberation Army General Hospital (304 Hospital), Beijing 100048,China
通讯作者：
通讯机构： [16]Betta Pharmaceuticals Co., Ltd, Hangzhou 311100, China [*1]Betta Pharmaceuticals Co., Ltd., 355 Xingzhong Road, Hangzhou 311100, China
推荐引用方式(GB/T 7714)：
Wen Zhang,Yiping Zhang,Qiong Zhao,et al.Long-term safety of icotinib in patients with non-small cell lung cancer: A retrospective, real-world study(Open Access)[J].JOURNAL OF THORACIC DISEASE.2020,12(3):639-650.doi:10.21037/jtd.2019.12.115.
APA：
Wen Zhang,Yiping Zhang,Qiong Zhao,Xiguang Liu,Likun Chen...&Fenlai Tan.(2020).Long-term safety of icotinib in patients with non-small cell lung cancer: A retrospective, real-world study(Open Access).JOURNAL OF THORACIC DISEASE,12,(3)
MLA：
Wen Zhang,et al."Long-term safety of icotinib in patients with non-small cell lung cancer: A retrospective, real-world study(Open Access)".JOURNAL OF THORACIC DISEASE 12..3(2020):639-650

相关文献

[1]The Main Treatment Failure Pattern for Completely Resected Stage II-IIIA (N1-N2) EGFR-Mutation Positive Lung Cancer [2]The Main Treatment Failure Pattern for Completely Resected Stage II-IIIA (N1-N2) EGFR-Mutation Positive Lung Cancer [3]The Main Treatment Failure Pattern for Completely Resected Stage II-IIIA (N1-N2) EGFR-Mutation Positive Lung Cancer [4]Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) [5]Synergistic effect of canakinumab with epidermal growth factor receptor tyrosine kinase inhibitors versus with chemotherapy for non-small cell lung cancer [6]Evaluation of epidermal growth factor receptor (EGFR) in nasopharyngeal carcinoma and lymph node metastases: Implications for EGFR targeted therapy [7]The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a systematic review and meta-analysis [8]Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18 [9]A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC) [10]Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients

资源点击量：52808 今日访问量：2 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号